François Ferré is the co-CEO of ALMA Lifesciences LLC, an investment and consulting firm. He is also the co-Chairman and co-Founder of AltheaDx, a privately-held company (spinoff of Althea Technologies) focusing on the development of pharmacogenomic tests. Dr. Ferre was the CEO of AltheaDx from 2010 to June 2013. Prior to AltheaDx, Dr. Ferré co-founded Althea Technologies and served as co-CEO from 1998 until 2008. He was a Director of Althea Technologies until April 2013 and has recently been appointed a Director of Ajinomoto-Althea after the acquisition of the company by Ajinomoto. He also currently serves on the board of a number of private companies: Algebraix Data, Biomatrica, Biological Dynamics (Chairman) and Portable Genomics. He is co-Chairman of the Advisory Board of MD Revolution. Dr. Ferré was the winner of the 2005 E&Y Entrepreneur of the Year award in the Life Sciences category. Dr. Ferré is a leader in gene quantification and biomarker development and has published several authoritative reviews on these topics, including the co-edition of a bestseller book on PCR with Nobel Prize winner, Dr. Kary Mullis. He received his PhD in molecular oncology from the Pasteur Institute, France, and did his post-doctoral training at the University of California, San Diego.